TOPIC: Cardiology; Oncology

ACCREDITATION TYPE: 1 AMA PRA Category 1 Credit(s)™ ; 1 ABIM MOC medical knowledge point

RELEASE DATE: November 18, 2021

EXPIRATION DATE: November 17, 2022

ESTIMATED TIME TO COMPLETE ACTIVITY: 60 minutes

This activity is jointly provided by The France Foundation and the International Cardio-Oncology Society.

TARGET AUDIENCE
This educational activity is intended for members of the cardiology and oncology healthcare teams who treat patients with cardiac amyloidosis, physicians (cardiologists and hematologists/oncologists), and advance practice providers (nurse practitioners and PAs).

STATEMENT OF NEED
There are significant challenges associated with the diagnosis and management of cardiac amyloidosis. While considered rare, this condition is almost certainly significantly underdiagnosed. Cardiac amyloidosis is influenced by several factors (eg, sex, age, geographic location, genetic factors, etc), is clinically heterogeneous, and can present as a number of other disorders (with subsequent delayed or misdiagnosis). Cardiac amyloidosis can also take several years and visits to many different specialists before an accurate diagnosis is made.

Early diagnosis and intervention is critical (including distinguishing ATTR from AL and other amyloidoses), yet does not occur typically as a consequence of the heterogeneity of the disease. Therapeutic options are indication-specific and limited, but there are emerging agents that clinicians may not be familiar with. Given the limited awareness of CA, there is a significant need for education about CA and the importance of early multidisciplinary diagnosis and management so patients can have the best possible outcomes.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES
Upon completing this activity, learners will be able to:

• Discuss contemporary therapy for TTR
• Discuss contemporary therapy for AL amyloidosis
• Summarize current standards of care and provide strategies for working in a multidisciplinary team

ACTIVITY FACULTY
Richard Cheng, MD, MSc
Associate Professor of Cardiology
Adjunct Associate Professor of Radiology
University of Washington Medical Center
Seattle, Washington

Ashutosh Wechalekar, MD
Professor of Medicine and Haematology
University College London
Honorary Consultant Haematologist
University College London Hospital/Royal Free Hospital
London, United Kingdom

Daniel Lenihan, MD
President
International Cardio-Oncology Society
United States

CREDIT DESIGNATION
Physicians: The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity
2. Review the activity objectives and CME/CE information
3. Complete the CME/CE activity
4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form at https://surveys.francefoundation.com/s3/9128-WEBINAR-SERIES-A-ZEBRA-OR-A-HORSE-Cardiac-Amyloidosis-Establish-the-Correct-Diagnosis-Web-4. This evaluation provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
6. Credit documentation/reporting:
• If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
• If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the International Cardio-Oncology Society (IC-OS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Faculty Disclosures–Activity Faculty
The faculty listed below report that they have no relevant financial relationships to disclose:

• Daniel Lenihan, MD
• Ashutosh Wechalekar, MD

The following faculty report that they have relevant financial relationships to disclose:

• Richard Cheng, MD: Clinical trial research funding paid to institutions (but none to individuals): Eidos Therapeutics and Ionis Pharmaceuticals

DISCLOSURE OF UNLABELED USE
TFF and IC-OS require that CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-OS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGEMENT
This activity is supported by an educational grant from Janssen Biotech, Inc., and administered by Janssen Scientific Affairs, LLC., Eidos Therapeutics Inc., and Pfizer Inc.